• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Maalox Suspension
    / Sanofi

    Active Ingredient *
    Aluminium Hydroxide 225 mg / 5 ml
    Magnesium Hydroxide 200 mg / 5 ml

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    355 ml

    full basket chart 1278 13007

    Related information


    Oral administration.
    Adults (including the elderly): 10-20 ml taken 20 minutes to one hour after meals and at bedtime or as required.
    Maalox can be taken with water or milk if required.
    Children: Not recommended for children under 14 years.


    Gastric or duodenal ulcer, gastritis, gastric hyperacidity.


    Hypersensitivity to the active ingredients or to any of the excipients.
    Maalox should not be used in patients who are severely debilitated or suffering from renal insufficiency, or if there is severe abdominal pain and/or the possibility of bowel obstruction.

    Special Precautions

    See prescribing information for full details.

    Side Effects

    See prescribing information for full details.

    Drug interactions

    Maalox should not be taken simultaneously with other medicines as they may interfere with their absorption.
    Antacids are known to interfere with the absorption of drugs such as tetracyclines, digoxin and vitamins, resulting in decreased absorption. This should be borne in mind when concomitant administration is considered.
    Aluminium-containing antacids may prevent the proper absorption of drugs such as ciprofloxacin, H2 antagonists, atenolol, cefdinir, cefpodoxime, hydroxychloroquine, chloroquine, chlorpromazine, rifampicin, cyclines, diflunisal, digoxin, bisphosphonates, ethambutol, fluoroquinolones, sodium fluorure, glucocorticoids, indomethacin, isoniazid, ketoconazole,
    levothyroxine, lincosamides, metoprolol, phenothiazine neuroleptics, penicillamine, propranolol, rosuvastatin, iron salts.
    Staggering the administration times of the interacting drug and the antacid by at least 2 hours (4 hours for the fluoroquinolones) will often help avoid undesirable drug interactions.
    Concomitant use with quinidines may increase the serum levels of quinidine and lead to quinidine overdosage.
    Polystyrene sulfonate (Kayexalate): Caution is advised when used concomitantly with polystyrene sulfonate (Kayexalate) due to the potential risks of reduced effectiveness of the resin in binding potassium, of metabolic alkalosis in patients with renal failure (reported with aluminium hydroxide and magnesium hydroxide), and of intestinal obstruction (reported with aluminium hydroxide).
    Aluminum hydroxide and citrates may result in increased aluminium levels, especially in patients with renal impairment.

    Pregnancy and Lactation

    Pregnancy: No clinical data on exposed pregnancies are available. Use of antacids should be avoided in the first trimester of pregnancy. Caution should be exercised when prescribing to pregnant and lactating women.
    Lactation: Because of the limited maternal absorption, when used as recommended, minimal amounts, if any, of aluminium hydroxide and magnesium salt combinations are expected to be excreted into breast milk.
    No effects on the breastfed newborns/infant are anticipated since the systemic exposure of the breastfeeding woman to aluminium hydroxide and magnesium hydroxide is negligible.


    Signs and symptoms: Reported symptoms of acute overdose with aluminium hydroxide and magnesium salts combination include diarrhea, abdominal pain, vomiting.
    Large doses of this product may trigger or aggravate intestinal obstruction and ileus in patients at risk.
    Management: Serious symptoms are unlikely following overdose. Discontinue medication and correct fluid deficiency if necessary.
    Aluminium and magnesium are eliminated through urinary route; treatment of acute overdose: consider administration of IV Calcium Gluconate, rehydration and forced diuresis.
    In case of renal function deficiency, haemodialysis or peritoneal dialysis is necessary.

    Sanofi-Aventis, S.P.A, Italy